
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc is poised for positive growth as its lead candidate, binimetinib, shows improved response rates among earlier line patients, indicating a strong potential for increased real-world efficacy of its pipeline agents. The company benefits from rising physician enthusiasm and a lower rate of treatment discontinuation compared to historical MEK inhibitors, enhancing the likelihood of broader clinical adoption, especially with potential guideline expansions. Additionally, the promising results of VS-7375 in non-small cell lung cancer (NSCLC) and the improved outcomes demonstrated in combinations with other treatments support Verastem's positioning in the competitive KRAS G12D landscape, fostering confidence in its sustainable market growth.
Bears say
Verastem Inc has faced ongoing operating losses since its inception, raising concerns about its potential to achieve profitability in the near future. The company's focus on KRAS inhibitors may be complicated by the lower response rates and adverse associations with KRAS wild-type variants, which could hinder the efficacy of their treatments in certain patient populations. Furthermore, the risk of failing to secure timely regulatory approvals or encountering delays could adversely affect investor confidence and the overall share price, emphasizing the challenging landscape the company is navigating.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares